UPDATE: Feltl & Company Raises PT to $22.10 on Insulet


20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


Feltl & Company reiterates its Buy rating on Insulet (NASDAQ: PODD) and increased its price target to $22.10 from $18.60 on better than expected guidance for revenues in 2012. Feltl & Company notes, "Insulet reported EPS of ($0.30) versus our ($0.27) estimate and ($0.26) consensus. Reported revenue came in at $47.2 million versus our $47.0 million estimate and $47.4 million consensus. Management guided 2012 revenue to a range of $210-$225 million versus our previous $207.7 million estimate. In addition, the company guided to a cash operating loss of ($10) million to breakeven, which was below our previous estimate of $8.2 million."PODD closed at $19.95 a share on Thursday.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorPrice TargetReiterationIntraday UpdateAnalyst RatingsFeltl & Company